The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Propofol Medium and Long Chain Fat Emulsion Injection (20ml: 0.2g and 10ml: 0.1g) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and being the first approved fat emulsion ampoule injection product of the Group. Propofol Medium and Long Chain Fat Emulsion Injection is a short-acting intravenous anesthetic for general anesthesia. It is mainly used for induction and maintenance of general anesthesia, sedation of patients undergoing diagnostic procedures and surgeries, and sedation of patients receiving assisted ventilation treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 HKD | +0.21% | +0.63% | -3.24% |
Apr. 23 | SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator | MT |
Apr. 16 | SSY Group Logs Nearly 15% Boost in Q1 Profit | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.24% | 1.81B | |
+34.00% | 704B | |
+27.80% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+15.17% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China